Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities

URLhttps://www.fujifilm.com/us/en/news/200_Million_Ce
SourceFujifilm
Date Published12/04/2023

Additional Reshoring Information:

Company/Division name Fujifilm Diosynth Biotechnologies
Parent companyFUJIFILM Holdings Corporation
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2023
Country(ies) from which reshored:Japan
City reshored to:Thousand Oaks
State(s) reshored to:CA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredCell therapies
What domestic positive factors made reshoring more attractive?Eco-system synergies
Find Reshoring Articles